99 related articles for article (PubMed ID: 34016893)
21. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
[TBL] [Abstract][Full Text] [Related]
22. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
23. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
24. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
26. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?
Crippa S; Bittoni A; Sebastiani E; Partelli S; Zanon S; Lanese A; Andrikou K; Muffatti F; Balzano G; Reni M; Cascinu S; Falconi M
Eur J Surg Oncol; 2016 Oct; 42(10):1533-9. PubMed ID: 27423449
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of Stereotactic Body Radiation Therapy for patient with unresectable liver metastases from colorectal cancer.
Py JF; Salleron J; Courrech F; Beckendorf V; Croisé-Laurent V; Peiffert D; Vogin G; Dietmann AS
Cancer Radiother; 2021 Jun; 25(4):350-357. PubMed ID: 33618909
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of Patients with Metastatic Breast Cancer Treated with Hypo-Fractionated Liver Radiotherapy.
Mushonga M; Helou J; Weiss J; Dawson LA; Wong RKS; Hosni A; Kim J; Brierley J; Koch CA; Alrabiah K; Lindsay P; Stanescu T; Barry A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345175
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
31. Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study).
Seidensticker M; Garlipp B; Scholz S; Mohnike K; Popp F; Steffen I; Seidensticker R; Stübs P; Pech M; PowerskI M; Hass P; Costa SD; Amthauer H; Bruns C; Ricke J
BMC Cancer; 2015 Jul; 15():517. PubMed ID: 26169362
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
33. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
34. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
35. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.
Cercek A; Boucher TM; Gluskin JS; Aguiló A; Chou JF; Connell LC; Capanu M; Reidy-Lagunes D; D'Angelica M; Kemeny NE
J Surg Oncol; 2016 Nov; 114(6):655-663. PubMed ID: 27566258
[TBL] [Abstract][Full Text] [Related]
36. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
38. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC; Iott MJ; Corsini MM
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):364-8. PubMed ID: 19735864
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S
BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104
[TBL] [Abstract][Full Text] [Related]
40. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors.
Clerici E; Comito T; Franzese C; Di Brina L; Tozzi A; Iftode C; Navarria P; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Apr; 196(4):325-333. PubMed ID: 31605163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
